MDT

100.26

+3%↑

147.57

+3.37%↑

VEEV

238.01

+7.61%↑

HQY

94.97

+1.71%↑

PHR.US

17.21

+0.53%↑

MDT

100.26

+3%↑

147.57

+3.37%↑

VEEV

238.01

+7.61%↑

HQY

94.97

+1.71%↑

PHR.US

17.21

+0.53%↑

MDT

100.26

+3%↑

147.57

+3.37%↑

VEEV

238.01

+7.61%↑

HQY

94.97

+1.71%↑

PHR.US

17.21

+0.53%↑

MDT

100.26

+3%↑

147.57

+3.37%↑

VEEV

238.01

+7.61%↑

HQY

94.97

+1.71%↑

PHR.US

17.21

+0.53%↑

MDT

100.26

+3%↑

147.57

+3.37%↑

VEEV

238.01

+7.61%↑

HQY

94.97

+1.71%↑

PHR.US

17.21

+0.53%↑

Начало・Списък с акции・Altimmune Inc

Altimmune Inc

Затворен

3.94 -3.19

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.86

Максимум

4.17

Ключови измерители
By Trading Economics
Приходи	3.1M -19M
Продажби	5K
Марж на печалбата	-380,280
Служители	59
EBITDA	4.4M -18M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+217.85% upside

Дивиденти
By Dow Jones
Следващи печалби	26.03.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	34M 384M
Предишно отваряне	7.13
Предишно затваряне	3.94

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

5.365 / 6.0486 Подкрепа & съпротива

Altimmune Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

6.01.2026 г., 21:14 ч. UTC

Значими двигатели на пазара

Ventyx Biosciences Gains on Report of Possible $1 Billion Eli Lilly Deal

6.01.2026 г., 19:23 ч. UTC

Придобивния, сливания и поглъщания

OneStream to Go Private Through $6.4 Billion Hg Acquisition

6.01.2026 г., 17:41 ч. UTC

Значими двигатели на пазара

Blink Charging Shares Rise as EV Chargers Begin Accepting Cryptocurrency

6.01.2026 г., 15:46 ч. UTC

Придобивния, сливания и поглъщания

Advent International Leads InPost Takeover Offer, Sky News Says

6.01.2026 г., 15:37 ч. UTC

Значими двигатели на пазара

Terrestrial Energy Shares Rise After DOE Agreement For Nuclear Plant Development

6.01.2026 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Decline After Hitting Record High -- Market Talk

6.01.2026 г., 23:35 ч. UTC

Пазарно говорене

Gold Edges Higher Amid Ongoing Geopolitical Tensions -- Market Talk

6.01.2026 г., 23:19 ч. UTC

Пазарно говорене

Greatland 2Q Gold Output Strong, Sales Soft -- Market Talk

6.01.2026 г., 22:53 ч. UTC

Пазарно говорене

WiseTech, REA and CAR Look Best Insulated From AI Threat -- Market Talk

6.01.2026 г., 22:03 ч. UTC

Придобивния, сливания и поглъщания

Staar Surgical: Merger Proposal Received 14.9M Votes For and 27.3M Against

6.01.2026 г., 22:03 ч. UTC

Придобивния, сливания и поглъщания

Staar Surgical, Which Earlier Reported Stockholder Rejection of Sale to Alcon, Reports Vote Totals

6.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

6.01.2026 г., 21:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

6.01.2026 г., 21:12 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

6.01.2026 г., 21:12 ч. UTC

Пазарно говорене

Commodity Demand Helps Canada Reduce Reliance on Trade With U.S. -- Market Talk

6.01.2026 г., 20:59 ч. UTC

Значими двигатели на пазара

Придобивния, сливания и поглъщания

Ventyx Biosciences Gains on Report of Possible $1B Eli Lilly Deal

6.01.2026 г., 20:40 ч. UTC

Придобивния, сливания и поглъщания

Acquisition of Ventyx Would Bring Lilly Into Emerging Category of Pills for Inflammation-Related Conditions -- WSJ

6.01.2026 г., 20:40 ч. UTC

Придобивния, сливания и поглъщания

Eli Lilly Nears Deal for Biotech Ventyx -- WSJ

6.01.2026 г., 20:40 ч. UTC

Придобивния, сливания и поглъщания

Deal Could Be Announced Imminently, Sources Say -- WSJ

6.01.2026 г., 20:40 ч. UTC

Придобивния, сливания и поглъщания

Eli Lilly in Advanced Talks to Buy Ventyx Biosciences For Over $1B, Sources Say -- WSJ

6.01.2026 г., 20:01 ч. UTC

Пазарно говорене

Oil Futures Give Back Post-Venezuela Incursion Gains -- Market Talk

6.01.2026 г., 19:52 ч. UTC

Пазарно говорене

U.S. Natural Gas Falls Awaiting Colder Weather -- Market Talk

6.01.2026 г., 19:46 ч. UTC

Придобивния, сливания и поглъщания

Under Armour Stock Rises After the 'Warren Buffet of Canada' Boosts Its Stake -- Barrons.com

6.01.2026 г., 19:08 ч. UTC

Придобивния, сливания и поглъщания

OneStream to Go Private Through $6.4B Hg Acquisition

6.01.2026 г., 18:28 ч. UTC

Придобивния, сливания и поглъщания

These Stocks Are Moving the Most Today: Sandisk, Nvidia, AMD, Palantir, OneStream, SoFi, Microchip, and More -- Barrons.com

6.01.2026 г., 17:20 ч. UTC

Пазарно говорене

Печалби

Financial Services Roundup: Market Talk

6.01.2026 г., 17:20 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Health Care Roundup: Market Talk

6.01.2026 г., 15:57 ч. UTC

Пазарно говорене

Crude Futures Ease Back From Early Gains -- Market Talk

6.01.2026 г., 15:34 ч. UTC

Пазарно говорене

Печалби

Bank of Montreal Expects to Exit 2027 With ROE Hitting 15% Target -- Market Talk

6.01.2026 г., 15:27 ч. UTC

Пазарно говорене

German Inflation Won't Fall Much Further in 2026 -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Altimmune Inc Прогноза

Ценова цел

By TipRanks

217.85% нагоре

12-месечна прогноза

Среден 13 USD 217.85%

Висок 14 USD

Нисък 12 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Altimmune Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

4 ratings

Купи

Задържане

Продай

Според 4 анализатори, дали борсови рейтинги на Altimmune Inc през последните 3 месеца.

Техническа оценка

By Trading Central

5.365 / 6.0486Подкрепа & съпротива

Recent bullish events outweigh bearish events.

All events are bearish.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Altimmune Inc

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.